Calpain-3 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Calpain-3 (UniProt P20807), expressed in HEK293 cells. Suited for calcium-dependent protease activity assays, substrate cleavage studies, inhibitor IC50 profiling, and Western blot antibody validation.
Expression system
HEK293
Cat. #
REC-Calpain3

In stock

SKU
REC-Calpain3
$498.00

Target Overview

Calpain-3 (UniProt P20807; gene CAPN3) is the 821-amino-acid, muscle-enriched member of the calpain family of calcium-regulated, non-lysosomal cysteine proteases (EC 3.4.22.54). Unlike ubiquitously expressed calpains-1 and -2, Calpain-3 contains three insertion sequences (IS1, IS2, and NS) absent from other family members, which confer autolytic regulation and underlie its skeletal-muscle-predominant expression pattern. This recombinant protein is produced in HEK293 cells, an expression system that supports the mammalian post-translational processing and folding required for enzymatic competence in cysteine proteases of this class. In biochemical settings, researchers use this recombinant to characterise calcium-concentration-dependent protease activity, define cleavage site specificity against defined peptide or protein substrates, and establish dose-response curves for small-molecule calpain inhibitors. Documented substrates include CtBP1 (cleaved at His-409) and p53/TP53, the latter degraded in a proteasome-independent manner in concert with USP25. These substrate relationships make this reagent directly applicable to studies of transcriptional co-repressor processing and tumour-suppressor turnover. For teams running antibody validation workflows, this recombinant serves as a well-defined positive control for Western blot and immunohistochemical detection. It pairs directly with the Triple Point Biologics anti-Calpain-3 polyclonal antibody (RP-Calpain3), allowing researchers to confirm band identity, optimise antibody titration, and establish specificity against the full-length 821-residue sequence in a single-reagent format. The HEK293 expression background also means the preparation is suitable for pull-down and co-immunoprecipitation experiments designed to identify novel Calpain-3 interactors under defined calcium conditions.

Background

Calpain-3 is the founding member of the tissue-restricted calpain subfamily and the only calpain isoform with demonstrated skeletal-muscle specificity at both expression and functional levels. Its protease activity is tightly coupled to intracellular calcium transients: at resting cytosolic calcium concentrations the enzyme is largely autolytically inactive, but upon calcium elevation it undergoes rapid N-terminal autolysis and subsequent cleavage of target substrates. This autolytic mechanism, along with the unique IS1 insertion that mediates titin binding at the N2A region of the sarcomere, distinguishes Calpain-3 from the classical μ- and m-calpain heterodimers and has driven considerable basic-research interest in understanding its physiological regulation. At the molecular level, Calpain-3 has been shown to cleave CtBP1 at His-409 and to mediate proteasome-independent degradation of the tumour suppressor p53/TP53, the latter in collaboration with USP25 (UniProt entry annotations; PubMed: 23357851, 27657329). These findings position it at the intersection of sarcomeric protein quality control, transcriptional regulation, and stress-response pathways — research contexts that extend well beyond muscle biology. Loss-of-function variants in CAPN3 are the molecular basis of Limb-Girdle Muscular Dystrophy R1 (LGMD R1, formerly LGMD2A), one of the most prevalent autosomal recessive muscular dystrophies worldwide. Published work has characterised how CAPN3 deficiency promotes inflammation-linked muscle atrophy through dysregulation of NF-κB signalling and impaired sarcomeric remodelling (Banerjee et al., Curr Issues Mol Biol, 2026). CAPN3 is also routinely interrogated in diagnostic genetic panels for muscular dystrophy cohorts, including tiered exome-sequencing strategies applied to geographically diverse patient populations (Rahmuni et al., Mol Genet Genomic Med, 2026). Separately, recent proteomic profiling of testicular tissue identified CAPN3 among differentially abundant proteins between non-obstructive and obstructive azoospermia cases (Wang et al., Asian J Androl, 2026), opening a line of inquiry into its role beyond striated muscle. In chromatin biology, protease-mediated dissociation of PRC1 components has been linked to H2AK119 ubiquitination remodelling during stress responses (Cui et al., EMBO J, 2026), a research context in which calpain family members including Calpain-3 are under active investigation as candidate executors of stimulus-dependent chromatin reorganisation. Recombinant Calpain-3 from HEK293 cells is the preferred in vitro tool for dissecting these substrate relationships, measuring inhibitor potency, and generating validated reference material for immunodetection assays — roles that collectively span muscle physiology, epigenetics, and cell biology research programmes.

Applications

  • Calcium-dependent cysteine protease activity assay using fluorogenic peptide substrates (e.g., Suc-LLVY-AMC)
  • Inhibitor IC50 determination for small-molecule calpain inhibitor profiling
  • Substrate cleavage validation: CtBP1 (His-409) and p53/TP53 processing in cell-free systems
  • Western blot positive control and antibody titration standard (pairs with RP-Calpain3)
  • Immunohistochemistry antibody validation using recombinant protein-coated controls
  • Pull-down and co-immunoprecipitation assays to identify Calpain-3 binding partners under defined [Ca²⁺] conditions
  • Autolytic processing studies: time-course SDS-PAGE analysis of IS1/IS2/NS insertion-dependent self-cleavage
  • Mass spectrometry-based substrate identification in skeletal-muscle protein lysate spiking experiments

References

  1. Wang Z et al. Proteomic insights into azoospermia: protein differences in testicular tissue between non-obstructive and obstructive azoospermia patients. Asian J Androl. 2026. doi:10.4103/aja2025114. PMID: 42210639
  2. Banerjee S et al. Inflammation-Linked Muscle Atrophy in Limb Girdle Muscular Dystrophy R1 (LGMDR1): Insights into Disease Mechanisms. Curr Issues Mol Biol. 2026. doi:10.3390/cimb48040361. PMID: 42042021
  3. Cui W et al. Protease-mediated PRC1 dissociation promotes H2AK119ub remodeling during stress responses. EMBO J. 2026. doi:10.1038/s44318-026-00729-9. PMID: 41813846
  4. Severa G et al. French National Protocol for Diagnosis and Care of Calpainopathy (LGMD R1/LGMD D4): consensus guidelines for clinical practice. Orphanet J Rare Dis. 2026. doi:10.1186/s13023-026-04279-5. PMID: 41761360
  5. Rahmuni Y et al. Implementing a Tiered Genetic Testing Strategy for Muscular Dystrophies in Morocco: From Targeted Assays to Exome Sequencing. Mol Genet Genomic Med. 2026. doi:10.1002/mgg3.70192. PMID: 41742649

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Cytoplasm; Ca²⁺-activated

Frequently Asked Questions

What is the expected molecular weight of recombinant Calpain-3 on SDS-PAGE?

Full-length human Calpain-3 (821 aa; UniProt P20807) has a predicted molecular weight of ~94 kDa. On reducing SDS-PAGE, the recombinant produced in HEK293 cells typically resolves as a predominant band near 94 kDa, consistent with the full-length precursor. Autolytic processing can generate fragments of ~58 kDa (C-terminal catalytic core) and ~36 kDa (N-terminal fragment); depending on calcium exposure during handling, you may observe these minor bands. Purity is confirmed at >95% by SDS-PAGE prior to release.

Does recombinant Calpain-3 undergo autolytic processing and which isoform is active?

Yes. Calpain-3 autolytically cleaves itself in a calcium-dependent manner, most prominently within its unique IS2 insertion. The full-length ~94 kDa form is considered the zymogen-like precursor; calcium activation triggers autolysis to yield an active ~58 kDa catalytic fragment. This recombinant is supplied as the full-length form with detectable enzymatic activity, allowing you to study both the intact enzyme and calcium-induced autolytic events in a single preparation. Minimize calcium exposure during aliquoting to preserve the full-length species if that is your experimental requirement.

What substrates can I use to measure Calpain-3 protease activity in a fluorescence assay?

For fluorometric activity assays, the fluorogenic peptide Suc-LLVY-AMC (50–200 µM) is a widely used calpain substrate and provides a reliable signal with Calpain-3 at 0.5–2 µg per reaction. Protein substrates with documented Calpain-3 cleavage sites include CtBP1 (cleaved at His-409) and p53/TP53. Assay buffer should contain 50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 1–5 mM CaCl₂; omitting CaCl₂ or including 5 mM EGTA serves as a negative control to confirm calcium dependence of the observed activity.

What buffer conditions optimize Calpain-3 activity and how do I set up a calcium titration?

Calpain-3 activity peaks in 50 mM Tris-HCl pH 7.5, 150 mM NaCl with free Ca²⁺ concentrations between 0.1 and 1 mM. For a calcium titration, buffer the free Ca²⁺ with EGTA/CaCl₂ mixtures using a tool such as MaxChelator to hit target free concentrations of 0.01, 0.1, 0.3, 1, and 5 mM. Include 5 mM DTT or 2 mM TCEP to maintain the active-site Cys105 in its reduced form. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is compatible with direct dilution into assay buffer; spin the diluted enzyme at 10,000 × g for 2 min before use to remove any aggregates.

What concentration of recombinant Calpain-3 should I use as a starting point for IC50 inhibitor assays?

A standard starting point for IC50 determinations is 1–2 µg recombinant Calpain-3 per 100 µL reaction (~130–260 nM based on ~94 kDa MW). Pre-incubate enzyme with the inhibitor for 15–30 min at room temperature in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT) before initiating the reaction by adding CaCl₂ and substrate. Include a vehicle-only control and a known calpain inhibitor such as MDL-28170 or calpeptin as reference compounds to bracket your IC50 curve and verify assay window quality before testing novel compounds.

How much recombinant Calpain-3 should I load for a Western blot positive control?

Load 50–200 ng per lane for a clean, non-saturated band at ~94 kDa when probing with anti-Calpain-3 antibody (SKU: RP-Calpain3). At 50 ng the band is readily detectable with standard ECL; at 200 ng autolytic fragments (~58 kDa, ~36 kDa) become visible, which can be useful for verifying antibody cross-reactivity across processed forms. Run the recombinant alongside your cell lysate in adjacent lanes so you have a migration reference and a confirmed-positive control on the same blot.

Can I use this recombinant as a positive control to validate the RP-Calpain3 antibody on Western blot?

Yes, and this is the primary cross-use case between these two catalog items. The matched rabbit polyclonal antibody (SKU: RP-Calpain3; see /anti-calpain-3-rabbit-polyclonal-antibody) was validated against recombinant Calpain-3 produced in HEK293 cells — the same expression system as this recombinant — so band identity is unambiguous. Load 50–100 ng of this recombinant as a defined positive control alongside your experimental lysates. This approach is particularly useful when establishing the antibody in a new tissue or cell type where endogenous Calpain-3 expression may be low or absent.

How should I store and handle recombinant Calpain-3 to maintain activity after arrival?

Upon receipt, centrifuge briefly at 500 × g, then aliquot into single-use volumes on dry ice and store at -20°C. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) stabilizes the enzyme through freeze-thaw, but repeated cycling will degrade activity. Avoid introducing CaCl₂ into stock aliquots — calcium triggers autolysis that will reduce full-length protein over time. For dilutions, use storage buffer supplemented with 1 mg/mL BSA for working concentrations below 50 µg/mL. Shelf life is 12 months from date of manufacture when stored continuously at -20°C.

Validation imagery coming soon

Western blot validation figures for REC-Calpain3 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →